Létourneau Isabelle J, Slot Andrew J, Deeley Roger G, Cole Susan P C
Department of Pharmacology and Toxicology, Division of Cancer Biology and Genetics, Cancer Research Institute, Queen's University, Kingston, Ontario, Canada.
Drug Metab Dispos. 2007 Aug;35(8):1372-9. doi: 10.1124/dmd.107.015479. Epub 2007 May 9.
The ATP-binding cassette multidrug resistance protein 1 MRP1 (ABCC1) mediates the cellular efflux of organic anions including conjugated metabolites, chemotherapeutic agents, and toxicants. We previously described a mutation in cytoplasmic loop 7 (CL7) of MRP1, Pro1150Ala, which reduced leukotriene C(4) (LTC(4)) transport but increased 17beta-estradiol 17beta-d-glucuronide (E(2)17betaG) and methotrexate (MTX) transport. Vanadate-induced trapping of [alpha-(32)P]8N(3)ADP by the Pro1150Ala mutant in the absence of substrate was also greatly reduced compared with wild-type MRP1 suggesting an uncoupling of ATP hydrolysis and transport activity. To determine whether the functional importance of MRP1-Pro(1150) is conserved, the analogous Pro(1158) and Pro(1147) residues in the MRP2 and MRP3 transporters, respectively, were mutated to Ala. Expression levels of the three mutants were unaffected; however, the vesicular transport activity of at least one organic anion substrate was significantly altered. As observed for MRP1-Pro1150Ala, LTC(4) transport by MRP2-Pro1158Ala was decreased. However, E(2)17betaG and MTX transport was comparable with that of wild-type MRP2 rather than increased as was observed for MRP1-Pro1150Ala. In the case of MRP3-Pro1147Ala, LTC(4) transport was increased, whereas E(2)17betaG transport was unaffected. MTX transport by MRP3-Pro1147Ala was also increased but to a lesser extent than for MRP1-Pro1150Ala. In contrast, all three mutants showed a marked reduction in levels of vanadate-induced trapped [alpha-(32)P]8N(3)ADP. We conclude that MRP1-Pro(1150), MRP2-Pro(1158), and MRP3-Pro(1147) in CL7 differ in their influence on substrate specificity but share a common role in the nucleotide interactions of these transporters.
ATP结合盒多药耐药蛋白1(MRP1,即ABCC1)介导包括结合代谢物、化疗药物和毒物在内的有机阴离子的细胞外排。我们之前描述了MRP1胞质环7(CL7)中的一个突变,即Pro1150Ala,该突变降低了白三烯C4(LTC4)的转运,但增加了17β-雌二醇17β-D-葡萄糖醛酸苷(E217βG)和甲氨蝶呤(MTX)的转运。与野生型MRP1相比,在无底物情况下,钒酸盐诱导的Pro1150Ala突变体捕获[α-(32)P]8N3ADP的能力也大大降低,这表明ATP水解与转运活性解偶联。为了确定MRP1-Pro(1150)的功能重要性是否保守,分别将MRP2和MRP3转运蛋白中类似的Pro(1158)和Pro(1147)残基突变为Ala。这三种突变体的表达水平未受影响;然而,至少一种有机阴离子底物的囊泡转运活性发生了显著改变。正如在MRP1-Pro1150Ala中观察到的那样,MRP2-Pro1158Ala对LTC4的转运减少。然而,E217βG和MTX的转运与野生型MRP2相当,而不像在MRP1-Pro1150Ala中那样增加。就MRP3-Pro1147Ala而言,LTC4的转运增加,而E217βG的转运未受影响。MRP3-Pro1147Ala对MTX的转运也增加了,但程度小于MRP1-Pro1150Ala。相反,所有三种突变体中钒酸盐诱导的捕获[α-(32)P]8N3ADP水平均显著降低。我们得出结论,CL7中的MRP1-Pro(1150)、MRP2-Pro(1158)和MRP3-Pro(1147)对底物特异性的影响不同,但在这些转运蛋白的核苷酸相互作用中具有共同作用。